Format

Send to

Choose Destination
Hum Mol Genet. 2014 Nov 15;23(22):6096-111. doi: 10.1093/hmg/ddu311. Epub 2014 Jun 18.

Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium.

Milne RL1, Burwinkel B2, Michailidou K3, Arias-Perez JI4, Zamora MP5, Menéndez-Rodríguez P4, Hardisson D6, Mendiola M7, González-Neira A8, Pita G8, Alonso MR8, Dennis J3, Wang Q3, Bolla MK3, Swerdlow A9, Ashworth A10, Orr N10, Schoemaker M11, Ko YD12, Brauch H13, Hamann U14; GENICA Network, Andrulis IL15, Knight JA16, Glendon G17, Tchatchou S18; kConFab Investigators; Australian Ovarian Cancer Study Group, Matsuo K19, Ito H20, Iwata H21, Tajima K22, Li J23, Brand JS24, Brenner H25, Dieffenbach AK25, Arndt V26, Stegmaier C27, Lambrechts D28, Peuteman G28, Christiaens MR29, Smeets A29, Jakubowska A30, Lubinski J30, Jaworska-Bieniek K30, Durda K30, Hartman M31, Hui M32, Yen Lim W32, Wan Chan C33, Marme F34, Yang R34, Bugert P35, Lindblom A36, Margolin S37, García-Closas M38, Chanock SJ39, Lissowska J40, Figueroa JD39, Bojesen SE41, Nordestgaard BG41, Flyger H42, Hooning MJ43, Kriege M43, van den Ouweland AM44, Koppert LB45, Fletcher O46, Johnson N46, dos-Santos-Silva I47, Peto J47, Zheng W48, Deming-Halverson S48, Shrubsole MJ48, Long J48, Chang-Claude J49, Rudolph A49, Seibold P49, Flesch-Janys D50, Winqvist R51, Pylkäs K51, Jukkola-Vuorinen A52, Grip M53, Cox A54, Cross SS55, Reed MW54, Schmidt MK56, Broeks A56, Cornelissen S56, Braaf L56, Kang D57, Choi JY58, Park SK57, Noh DY59, Simard J60, Dumont M60, Goldberg MS61, Labrèche F62, Fasching PA63, Hein A64, Ekici AB65, Beckmann MW64, Radice P66, Peterlongo P67, Azzollini J68, Barile M69, Sawyer E70, Tomlinson I71, Kerin M72, Miller N72, Hopper JL73, Schmidt DF73, Makalic E73, Southey MC74, Hwang Teo S75, Har Yip C76, Sivanandan K77, Tay WT78, Shen CY79, Hsiung CN80, Yu JC81, Hou MF82, Guénel P83, Truong T83, Sanchez M83, Mulot C84, Blot W85, Cai Q85, Nevanlinna H86, Muranen TA86, Aittomäki K87, Blomqvist C88, Wu AH89, Tseng CC89, Van Den Berg D89, Stram DO89, Bogdanova N90, Dörk T91, Muir K92, Lophatananon A93, Stewart-Brown S93, Siriwanarangsan P94, Mannermaa A95, Kataja V96, Kosma VM95, Hartikainen JM95, Shu XO48, Lu W97, Gao YT98, Zhang B48, Couch FJ99, Toland AE100; TNBCC, Yannoukakos D101, Sangrajrang S102, McKay J103, Wang X104, Olson JE105, Vachon C105, Purrington K105, Severi G106, Baglietto L106, Haiman CA89, Henderson BE89, Schumacher F89, Le Marchand L107, Devilee P108, Tollenaar RA109, Seynaeve C43, Czene K24, Eriksson M24, Humphreys K24, Darabi H24, Ahmed S110, Shah M110, Pharoah PD111, Hall P24, Giles GG106, Benítez J112, Dunning AM110, Chenevix-Trench G113, Easton DF111.

Collaborators (153)

Berchuck A, Eeles RA, Al Olama AA, Kote-Jarai Z, Benlloch S, Antoniou A, McGuffog L, Offit K, Lee A, Dicks E, Luccarini C, Tessier DC, Bacot F, Vincent D, LaBoissière S, Robidoux F, Nielsen SF, Cunningham JM, Windebank SA, Hilker CA, Meyer J, Angelakos M, Maskiell J, van der Schoot E, Rutgers E, Verhoef S, Hogervorst F, Boonyawongviroj P, Siriwanarungsan P, Schrauder M, Rübner M, Oeser S, Landrith S, Williams E, Ryder-Mills E, Sargus K, McInerney N, Colleran G, Rowan A, Jones A, Sohn C, Schneeweiß A, Bugert P, Alvarez N, Lacey J, Wang S, Ma H, Lu Y, DeHart JC, Deapen D, Pinder R, Lee E, Schumacher F, Horn-Ross P, Reynolds P, Nelson D, Park H, Ziegler H, Wolf S, Hermann V, Lo WY, Justenhoven C, Baisch C, Fischer HP, Brüning T, Pesch B, Rabstein S, Lotz A, Harth V, Heikkinen T, Erkkilä I, Aaltonen K, von Smitten K, Antonenkova N, Hillemanns P, Christiansen H, Myöhänen E, Kemiläinen H, Thorne H, Niedermayr E, Bowtell D, Chenevix-Trench G, deFazio A, Gertig D, Green A, Webb P, Green A, Parsons P, Hayward N, Webb P, Whiteman D, Fung A, Yashiki J, Peuteman G, Smeets D, Van Brussel T, Corthouts K, Obi N, Heinz J, Behrens S, Eilber U, Celik M, Olchers T, Manoukian S, Peissel B, Scuvera G, Zaffaroni D, Bonanni B, Feroce I, Maniscalco A, Rossi A, Bernard L, Tranchant M, Valois MF, Turgeon A, Heguy L, Sze Yee P, Kang P, Nee KI, Mariapun S, Sook-Yee Y, Lee D, Ching TY, Taib NA, Otsukka M, Mononen K, Selander T, Weerasooriya N, Krol-Warmerdam E, Molenaar J, Blom J, Brinton L, Szeszenia-Dabrowska N, Peplonska B, Zatonski W, Chao P, Stagner M, Bos P, Blom J, Crepin E, Nieuwlaat A, Heemskerk A, Higham S, Cross S, Cramp H, Connley D, Balasubramanian S, Brock I, Luccarini C, Conroy D, Baynes C, Chua K, Pilarski R.

Author information

1
Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, Human Cancer Genetics Programme, roger.milne@cancervic.org.au.
2
Department of Obstetrics and Gynecology, Molecular Epidemiology Group.
3
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care.
4
Servicio de Cirugía General y Especialidades, Hospital Monte Naranco, Oviedo, Spain.
5
Servicio de Oncología Médica, Hospital Universitario La Paz, Madrid, Spain.
6
Department of Pathology, Hospital Universitario La Paz, IdiPAZ (Hospital La Paz Institute for Health Research) Universidad Autonoma de Madrid, Madrid, Spain.
7
Laboratory of Pathology and Oncology, Research Unit, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain.
8
Human Genotyping-CEGEN Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
9
Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, UK, Division of Breast Cancer Research.
10
Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research.
11
Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, UK.
12
Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany.
13
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany, University of Tübingen, Tübingen, Germany.
14
Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany.
15
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada, Department of Molecular Genetics.
16
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada, Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
17
Ontario Cancer Genetics Network, Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada.
18
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
19
Department of Preventive Medicine, Kyushu University Faculty of Medical Sciences, Fukuoka, Japan.
20
Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan.
21
Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
22
Department of Public Health & Occupational Medicine, Mie University Graduate School of Medicine, Tsu, Japan.
23
Human Genetics Division, Genome Institute of Singapore, Singapore.
24
Department of Medical Epidemiology and Biostatistics.
25
Division of Clinical Epidemiology and Aging Research, German Cancer Consortium (DKTK), Heidelberg, Germany.
26
Division of Clinical Epidemiology and Aging Research.
27
Saarland Cancer Registry, Saarbrücken, Germany.
28
Vesalius Research Center (VRC), VIB, Leuven, Belgium.
29
Multidisciplinary Breast Center, University Hospital Gasthuisberg, Leuven, Belgium.
30
Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
31
Saw Swee Hock School of Public Health, Department of Surgery, Yong Loo Lin School of Medicine.
32
Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore.
33
Department of Surgery, National University Health System, Singapore, Singapore.
34
Department of Obstetrics and Gynecology, National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.
35
Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
36
Department of Molecular Medicine and Surgery.
37
Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
38
Division of Breast Cancer Research, Breakthrough Breast Cancer Research Centre, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA, Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
39
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
40
Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center & Institute of Oncology, Warsaw, Poland.
41
Copenhagen General Population Study, Herlev Hospital, Department of Clinical Biochemistry, Herlev Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
42
Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
43
Department of Medical Oncology.
44
Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.
45
Department of Surgical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
46
Breakthrough Breast Cancer Research Centre.
47
London School of Hygiene and Tropical Medicine, London, UK.
48
Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
49
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
50
Institute for Medical Biometrics and Epidemiology, Department of Cancer Epidemiology/Clinical Cancer Registry, University Clinic Hamburg-Eppendorf, Hamburg, Germany.
51
Laboratory of Cancer Genetics and Tumor Biology, Department of Clinical Chemistry and Biocenter Oulu, University of Oulu, Northern Finland Laboratory Centre NordLab, Oulu, Finland.
52
Department of Oncology.
53
Department of Surgery, Oulu University Hospital, University of Oulu, Oulu, Finland.
54
CRUK/YCR Sheffield Cancer Research Centre, Department of Oncology.
55
Academic Unit of Pathology, Department of Neuroscience, University of Sheffield, Sheffield, South Yorkshire, UK.
56
Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
57
Department of Preventive Medicine, Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea, Cancer Research Institute, Seoul National University, Seoul, Korea.
58
Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea, Cancer Research Institute, Seoul National University, Seoul, Korea.
59
Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.
60
Genomics Center, Centre Hospitalier Universitaire de Québec Research Center and Laval University, QC, Canada.
61
Department of Medicine, McGill University, Montreal, QC, Canada, Division of Clinical Epidemiology, McGill University Health Centre, Royal Victoria Hospital, Montreal, QC, Canada.
62
Département de médecine sociale et préventive, Département de santé environnementale et santé au travail, Université de Montréal, Montreal, QC, Canada.
63
University Breast Center Franconia, Department of Gynecology and Obstetrics, David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, CA, USA.
64
University Breast Center Franconia, Department of Gynecology and Obstetrics.
65
Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
66
Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine.
67
IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy.
68
Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy.
69
Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia (IEO), Milan, Italy.
70
Division of Cancer Studies, NIHR Comprehensive Biomedical Research Centre, Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London, London, UK.
71
Wellcome Trust Centre for Human Genetics, Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
72
School of Medicine, Clinical Science Institute, National University of Ireland, Galway, Ireland.
73
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health.
74
Department of Pathology, The University of Melbourne, Melbourne, Australia.
75
Cancer Research Initiatives Foundation, Sime Darby Medical Centre, Subang Jaya, Malaysia, Breast Cancer Research Unit, University Malaya Cancer Research Institute, University Malaya Medical Centre, Kuala Lumpur, Malaysia.
76
Breast Cancer Research Unit, University Malaya Cancer Research Institute, University Malaya Medical Centre, Kuala Lumpur, Malaysia.
77
Cancer Research Initiatives Foundation, Sime Darby Medical Centre, Subang Jaya, Malaysia.
78
Singapore Eye Research Institute, National University of Singapore, Singapore, Singapore.
79
Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, College of Public Health, China Medical University, Taichong, Taiwan.
80
Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
81
Tri-Service General Hospital, Taipei, Taiwan.
82
Cancer Center, Department of Surgery, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan.
83
Inserm (National Institute of Health and Medical Research), CESP (Center for Research in Epidemiology and Population Health), U1018, Environmental Epidemiology of Cancer, Villejuif, France, University Paris-Sud, UMRS 1018, Villejuif, France.
84
Inserm (National Institute of Health and Medical Research), U775, Paris, France, Centre de Ressources Biologiques EPIGENETEC, Paris, France.
85
Department of Medicine, Vanderbilt University, Nashville, TN, USA.
86
Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
87
Department of Clinical Genetics.
88
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
89
Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
90
Department of Obstetrics and Gynaecology, Department of Radiation Oncology, Hannover Medical School, Hannover, Germany.
91
Department of Obstetrics and Gynaecology.
92
Institute of Population Health, University of Manchester, Manchester, UK, Division of Health Sciences, Warwick Medical School, Coventry, UK.
93
Division of Health Sciences, Warwick Medical School, Coventry, UK.
94
Ministry of Public Health, Thailand.
95
School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, Biocenter Kuopio, Department of Clinical Pathology.
96
Biocenter Kuopio, School of Medicine, Institute of Clinical Medicine, Oncology, University of Eastern Finland, Kuopio, Finland, Cancer Center, Kuopio University Hospital, Kuopio, Finland.
97
Shanghai Center for Disease Control and Prevention, Shanghai, China.
98
Shanghai Cancer Institute, Shanghai, China.
99
Department of Laboratory Medicine and Pathology, Department of Health Sciences Research.
100
Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
101
Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research 'Demokritos', Athens, Greece.
102
National Cancer Institute, Bangkok, Thailand.
103
Genetic Susceptibility Group, International Agency for Research on Cancer, Lyon, France.
104
Department of Laboratory Medicine and Pathology.
105
Department of Health Sciences Research.
106
Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health.
107
University of Hawaii Cancer Center, Honolulu, HI, USA.
108
Department of Human Genetics and.
109
Department of Surgical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
110
Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
111
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
112
Human Cancer Genetics Programme, Human Genotyping-CEGEN Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
113
QIMR Berghofer Institute of Medical Research, Brisbane, Australia.

Abstract

Candidate variant association studies have been largely unsuccessful in identifying common breast cancer susceptibility variants, although most studies have been underpowered to detect associations of a realistic magnitude. We assessed 41 common non-synonymous single-nucleotide polymorphisms (nsSNPs) for which evidence of association with breast cancer risk had been previously reported. Case-control data were combined from 38 studies of white European women (46 450 cases and 42 600 controls) and analyzed using unconditional logistic regression. Strong evidence of association was observed for three nsSNPs: ATXN7-K264R at 3p21 [rs1053338, per allele OR = 1.07, 95% confidence interval (CI) = 1.04-1.10, P = 2.9 × 10(-6)], AKAP9-M463I at 7q21 (rs6964587, OR = 1.05, 95% CI = 1.03-1.07, P = 1.7 × 10(-6)) and NEK10-L513S at 3p24 (rs10510592, OR = 1.10, 95% CI = 1.07-1.12, P = 5.1 × 10(-17)). The first two associations reached genome-wide statistical significance in a combined analysis of available data, including independent data from nine genome-wide association studies (GWASs): for ATXN7-K264R, OR = 1.07 (95% CI = 1.05-1.10, P = 1.0 × 10(-8)); for AKAP9-M463I, OR = 1.05 (95% CI = 1.04-1.07, P = 2.0 × 10(-10)). Further analysis of other common variants in these two regions suggested that intronic SNPs nearby are more strongly associated with disease risk. We have thus identified a novel susceptibility locus at 3p21, and confirmed previous suggestive evidence that rs6964587 at 7q21 is associated with risk. The third locus, rs10510592, is located in an established breast cancer susceptibility region; the association was substantially attenuated after adjustment for the known GWAS hit. Thus, each of the associated nsSNPs is likely to be a marker for another, non-coding, variant causally related to breast cancer risk. Further fine-mapping and functional studies are required to identify the underlying risk-modifying variants and the genes through which they act.

PMID:
24943594
PMCID:
PMC4204770
DOI:
10.1093/hmg/ddu311
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Publication types

MeSH terms

Substances

Grant support

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center